Loading VIJAYA price...
Peers are the listed companies in the exchange's own industry group: Healthcare Service Provider. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 6 Aug 2026), sales rose 22.8% from a year earlier to Rs 231 cr and profit rose 37.6% to Rs 53.1 cr.
- Return on equity stayed above 15% from FY24 to FY26 (lowest 18.0%).
- No borrowings at the FY26 balance sheet.
- Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 19 results, the share rose on 10 and fell on 9, and moved by 3% or more on 9.
Q1 FY27: results filed 6 Aug 2026. The share went from its close on 5 Aug 2026 to its close on 7 Aug 2026 -2.77%.
Of every Rs 100 of sales in FY26, Rs 59 went on running costs, Rs 11 on depreciation, Rs 4.1 on interest and Rs 7.3 on tax; Rs 21 was left as profit.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | - | 24.4% | 19.5% |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | - | 40.3% | 40.1% | 41.4% |
| Net marginProfit after everything, per Rs 100 of sales. | - | 21.8% | 21.1% | 21.2% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | 18.1% | 18.0% | 18.1% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | 17.1% | 20.1% | 19.8% | 19.2% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | - | 7.6x | 8.2x | 8.0x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 1,507 Cr of assets. Its owners funded 64% of that, with no borrowings.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 271 Cr, spent Rs 183 Cr on plant and equipment, and cash rose by Rs 27 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| LALPATHLAB Dr. Lal Path Labs Ltd. | 31,100 cr | 44.8x | 12.4x | 21.5% | 25.7% | 0.00 | 18.9% | +19.1% | 0.72% |
| VIJAYA Vijaya Diagnostic Centre Limited | 14,362 cr | 76.7x | 15.0x | 19.6% | 19.2% | 0.00 | 21.9% | +22.8% | 0.14% |
| METROPOLIS Metropolis Healthcare Limited | 10,989 cr | 22.8x | 7.3x | 13.3% | 15.7% | 0.01 | 11.9% | +16.6% | 0.19% |
| THYROCARE Thyrocare Technologies Limited | 7,491 cr | 27.6x | 12.8x | 30.0% | 33.6% | 0.00 | 20.1% | +24.3% | 1.98% |
| NEPHROPLUS Nephrocare Health Services Limited | 6,095 cr | - | 5.5x | - | 13.7% | 0.07 | - | - | 0.00% |
| SURAKSHA Suraksha Diagnostic Limited | 1,628 cr | 45.4x | 6.7x | 14.4% | 14.7% | 0.01 | 10.8% | +20.8% | 0.00% |
| KRSNAA Krsnaa Diagnostics Limited | 1,617 cr | 16.8x | 1.6x | 9.9% | 10.6% | 0.55 | 11.9% | +22.1% | 0.55% |
| HEALTHX Health X Platform Limited | 857 cr | - | 1.3x | -3.4% | - | - | -1.8% | +49.7% | 0.00% |
| GAUDIUMIVF Gaudium IVF and Women Health Limited | 674 cr | - | 4.4x | - | 23.1% | 0.15 | - | - | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from 40.3% to 41.4% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2026 has paid Rs 2.00 per share, about Rs 143 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.